Scienture Holdings, Inc. (SCNX) - Dilution Analysis

10-Q filing | 40.6M shares outstanding

10-K filing | 40.6M shares outstanding

S-3 filing: Scienture Holdings, Inc. is filing a registration statement for a proposed public offering of up to $200 million of various securities, including common stock, preferred stock, and debt securities, which may be sold from time to time.

8-K filing: Scienture Holdings, Inc. sold an aggregate of 754,716 shares of its common stock to BlueCap Ventures LLC, Jinal Sheth, Nimish Sheth, and Chintan Shah at a price of $1.59 per share, receiving approximately $1.2 million in aggregate proceeds. ($1.2M proceeds)

POS AM filing: The Registration Statement registered the future resale of up to 4,300,000 shares of common stock held by Arena Finance Markets, LP, Arena Special Opportunities Partners III, LP, and Arena Business Solutions Global SPC II, Ltd pursuant to purchase agreements.

10-Q filing | 13.1M shares outstanding

S-1 filing: This S-1 filing registers for resale up to 2,643,421 shares of common stock issuable upon conversion of the First Closing Debentures, and outlines an Equity Line of Credit with Arena Global for up to $50,000,000.

10-K filing | 12.5M shares outstanding

8-K filing: Scienture Holdings, Inc. entered into a consulting agreement with Draper, Inc., issuing 100,000 restricted shares of the Company's common stock as compensation for consulting services.

S-1/A filing: This S-1/A filing describes an offering of up to 4,300,000 shares of common stock by selling stockholders and an equity line purchase agreement for up to $50,000,000 with Arena Global.

S-1/A filing: S-1/A filing for offering of common stock by selling stockholders and potential sales under ELOC Purchase Agreement.

S-1/A filing: This S-1/A filing includes information on up to 4,300,000 shares of common stock offered by selling stockholders and up to $50,000,000 in gross proceeds under the ELOC Purchase Agreement in connection with sales of common stock to Arena Global.

S-1 filing: This S-1 filing includes an offering of up to 4,300,000 shares of common stock by selling stockholders and a potential offering of up to $50,000,000 of common stock to Arena Global through an ELOC Purchase Agreement.

8-K filing: Scienture Holdings, Inc. issued Debentures to Arena Investors for $3,000,000 and issued 55,000 shares of common stock as consideration for the First Closing, and entered into an Equity Line of Credit (ELOC) agreement with Arena Business Solutions Global SPC II, Ltd, agreeing to issue 70,000 shares of common stock as an initial commitment fee, and consented to the transfer of 50,000 shares of company common stock to NVK Finance, LLC.

10-Q filing | 8.6M shares outstanding

8-K filing: On September 20, 2024, all previously issued shares of Series X Preferred Stock of Scienture Holdings, Inc. were converted into a total of 6,826,713 shares of the Company's common stock. Following the completion of the conversion, the Company had 8,576,795 shares of Common Stock outstanding.

10-Q filing | 1.4M shares outstanding

8-K filing: TRxADE HEALTH, INC. entered into a Merger Agreement with Scienture, Inc. on July 25, 2024, resulting in Scienture becoming a wholly-owned subsidiary of TRxADE HEALTH, INC. and TRxADE HEALTH, INC. issuing 291,555 shares of common stock and 6,826,713 shares of Series X Non-Voting Convertible Preferred Stock to Scienture's shareholders.

10-Q filing | 1.3M shares outstanding

10-K filing | 1.4M shares outstanding

8-K filing: TRxADE HEALTH Inc. sold all of the issued and outstanding stock of its subsidiary Superlatus Inc. to Superlatus Foods Inc. for $1.00, and TRxADE Inc. agreed to invest up to $5.0 million in Lafayette Energy Corp. in exchange for Series A Convertible Preferred Stock. ($5.0M proceeds)

10-Q filing | 1.2M shares outstanding

8-K filing: TRxADE HEALTH, Inc. amended its Merger Agreement with Superlatus, adjusting the merger consideration to 1,712,328 shares of TRxADE's common stock at $7.30 per share, which includes 136,441 common shares and Series B preferred stock (convertible at 100:1), and shareholders of Superlatus agreed to surrender back to the Company 289,731 shares of the Company's Series B preferred stock.

8-K filing: TRxADE HEALTH, Inc. sold 290 shares of Series C Convertible Preferred Stock and a warrant to purchase up to 41,193 shares of Common Stock to Hudson Global Ventures, LLC in a private placement, and issued an additional 40,000 shares of Common Stock as commitment shares, resulting in gross proceeds of $290,000. ($0.29M proceeds)

10-Q filing | 1.2M shares outstanding

8-K filing: TRxADE HEALTH, Inc. completed its acquisition of Superlatus, Inc. on July 31, 2023, issuing 136,441 shares of common stock and 306,855 shares of Series B Preferred Stock to Superlatus shareholders, and issued non-transferrable rights to shareholders.

8-K filing: TRxADE HEALTH, Inc. entered into an Amended and Restated Agreement and Plan of Merger with Superlatus, Inc., involving the issuance of 30,821,941 shares (including common stock and Series B Preferred Stock) to Superlatus shareholders and the issuance of non-transferrable rights to TRxADE HEALTH shareholders to receive one share of common stock for every seven shares held.

8-K filing: TRxADE Health, Inc. entered into a Merger Agreement with Superlatus Inc., issuing 136,436 shares of common stock and 37,027 shares of Series B Preferred Stock to Superlatus shareholders, and also entered into a Stock Swap Agreement with Principal Stockholders for 166,666 shares of common stock.

8-K filing: TRxADE HEALTH, INC. entered into a binding letter of intent for a merger with Superlatus, Inc., where Superlatus shareholders will receive 30,821,918 shares of the Company, valued at $7.30 per share, comprised of common and non-voting preferred stock.

8-K filing: TRxADE HEALTH, Inc. entered into a letter of intent for a merger with Superlatus, Inc., where Superlatus shareholders will receive 3,839,176 shares of TRxADE HEALTH, Inc., valued at $58.61 per share, comprised of common and non-voting preferred stock, representing 19.99% of total outstanding common stock after the merger.

8-K filing: Stock split 1-for-15 | Outstanding: 10,060,735 → 670,715

10-Q filing | 10.1M shares outstanding

S-1 filing: TRxADE Health, Inc. is offering shares of common stock in a firm commitment underwritten public offering, with the offering price to be determined by negotiations between the company and the underwriters. The company has granted the underwriters a 45-day option to purchase additional shares to cover over-allotments.

10-K filing | 10.1M shares outstanding

8-K filing: On January 4, 2023, the holder of 601,740 pre-funded warrants exercised them for nominal consideration, and the company is in the process of issuing 601,740 shares of common stock.

S-1 filing: This S-1 filing registers shares of common stock held by a selling stockholder, allowing for their resale from time to time. The company will not receive any proceeds from these sales, but may receive proceeds from the exercise of private placement warrants.

10-Q filing | 9.3M shares outstanding

8-K filing: TRxADE HEALTH, INC. completed a private placement offering, selling 920,000 shares of common stock, pre-funded warrants to purchase up to 601,740 shares, and private warrants to purchase up to 2,662,045 shares, resulting in gross proceeds of approximately $1.75 million. ($1.75M proceeds)

8-K filing: On August 31, 2022, the Board of Directors approved the issuance of 54,525 shares of common stock to each independent member of the Board of Directors for services rendered during fiscal 2022, valued at $63,250 based on the closing sales price on the approval date.

S-3 filing: TRxADE Health, Inc. files an S-3 form to register the offering of common stock, preferred stock, debt securities, warrants, or a combination of these securities for an aggregate initial offering price of up to $100 million.

10-Q filing | 8.2M shares outstanding

10-Q filing | 8.2M shares outstanding

10-K filing | 8.2M shares outstanding

8-K filing: TRxADE HEALTH, INC. authorized and approved the resumption of the Company's prior share repurchase program to allow for the repurchase of up to 100,000 of the currently outstanding shares of the Company's common stock.

10-Q filing | 8.2M shares outstanding

10-Q filing | 8.1M shares outstanding

10-Q filing | 8.1M shares outstanding

10-K filing | 6.5M shares outstanding

10-Q filing | 6.0M shares outstanding

S-3 filing: Trxade Group, Inc. files an S-3 form to register an indeterminate number of common stock, preferred stock, debt securities and warrants to purchase common stock, preferred stock and debt securities for an aggregate initial offering price not to exceed $100,000,000.

10-Q filing | 6.1M shares outstanding

8-K filing: Gajan Mahendiran, a greater than 5% beneficial owner of Trxade Group, Inc., exercised warrants to purchase 335,002 shares of common stock at an exercise price of $0.06, providing the Company with $20,100 on June 25, 2020. ($0.02M proceeds)

8-K filing: The Board of Directors and Compensation Committee of Trxade Group, Inc. amended the performance metrics for Suren Ajjarapu, the Company's Chief Executive Officer, to vest 49,020 shares of restricted stock previously issued under the Company's 2019 Equity Compensation Plan.

10-Q filing | 6.0M shares outstanding

8-K filing: Trxade Group, Inc. granted stock options and awarded shares of common stock to employees and directors, including bonuses and restricted stock grants, under the 2019 Equity Compensation Plan.

10-K filing | 5.9M shares outstanding

8-K filing: The underwriters exercised their overallotment option and purchased 115,767 shares of the Company's common stock at a net price of $5.98 per share on February 21, 2020.

8-K filing: Trxade Group, Inc. closed its firm commitment underwritten offering of 806,452 shares of common stock at a price of $6.50 per share, resulting in gross proceeds of approximately $5.24 million. ($5.24M proceeds)

S-1/A filing: This S-1/A filing relates to a proposed offering of common stock with the intention to use the net proceeds from this offering to fund working capital and general corporate purposes and possibly acquisitions of other companies, products or technologies.

S-1/A filing: Trxade Group, Inc. is offering up to 806,452 shares of common stock in a firm commitment underwritten public offering, with an over-allotment option for underwriters to purchase up to an additional 120,967 shares.

S-1/A filing: Trxade Group, Inc. is offering up to 806,452 shares of common stock in a firm commitment underwritten public offering.